Lecanemab-irmb (Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the population in which the drug was initiated in clinical trials. Lecanemab is the second IV amyloid-beta directed monoclonal antibody to be approved for this indication; aducanumab (Aduhelm) was approved in 2021 and has the same restrictions on treatment initiation.1,2
...- Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis
- Epsolay - A Benzoyl Peroxide Cream for Rosacea
- Transdermal Dextroamphetamine (Xelstrym) for ADHD
- COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant (online only)
- In Brief: A New Indication for Dabrafenib (Tafinlar) and Trametinib (Mekinist) Combination Therapy (online only)
- Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)
- Tremelimumab (Imjudo) for Metastatic NSCLC (online only)
- Hemgenix - A Gene Therapy for Hemophilia B
- Topical Roflumilast (Zoryve) for Plaque Psoriasis
- Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
- In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure
- In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease
- Adagrasib (Krazati) for NSCLC (online only)
- Opdualag for Metastatic Melanoma (online only)
RELEASE
Three products are currently available in the US for treatment of high-risk,1 nonhospitalized adults with mild to moderate COVID-19: oral ritonavir-boosted nirmatrelvir (Paxlovid), IV remdesivir (Veklury), and oral molnupiravir (Lagevrio). Remdesivir is FDA-approved for such use; nirmatrelvir/ritonavir and molnupiravir are available under an FDA Emergency Use Authorization. Because the pivotal clinical trials of these products for outpatient use were …